Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Latent Tuberculosis Infection: A Guide for Primary Health Care Providers

Return to Table of Contents

References

American Academy of Pediatrics. Tuberculosis. Red Book: 2012 Report of the Committee on Infectious Diseases. L.K. Pickering (Ed.), 29th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2012: 736-759.

ATS/CDC/IDSA. Treatment of tuberculosis. MMWR 2003;52 (No. RR-11).

CDC. Targeted tuberculin testing and treatment of latent TB infection. MMWR 2000;49 (No. RR-6).

CDC. Update: adverse event data and revised American Thoracic Society/CDC. Recommendations against the use of rifampin and pyrazinamide for the treatment of latent tuberculosis infection—United States, 2003. MMWR 2003;52(31):735-9.

CDC. Tuberculosis associated with blocking agents against tumor necrosis factor – alpha – California, 2002–2003. MMWR 2004; 53 (No.30).

CDC. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2004;53 (2):37.

CDC. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009; 58 (No. RR4): 1-198.

CDC. Guidelines for prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR 2009; 58 (No. RR 11): 1-166.

CDC. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection – United States – 2010. MMWR 2010;59(RR05).

CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR 2011;60(48); 1650-1653.

Reichman, LB, Bhavaraju, R, eds. Guidelines for the Diagnosis of Latent Tuberculosis Infection in the 21st Century, 2nd Edition. Newark: New Jersey Medical School Global Tuberculosis Institute; 2008.

TOP